The strong Q3 beat and reaffirmed guidance suggest the pay-as-you-go pharmacy channel is scaling effectively. Monitor the Q4 earnings call for 2027 guidance and further pharmacy formulary expansion updates.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $16.91entry
- T+1 · 8d ago +7.45%α +5.08% · $18.17
- T+5 · 4d ago +18.69%α +16.09% · $20.07
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Tandem Diabetes Care reported Q3 2026 sales of $283.7M (+14% YoY), above the $265.8M consensus, and a GAAP net loss per share of -$0.10, beating the consensus estimate of -$0.24. The company reaffirmed its full-year 2026 guidance for sales of $1.065B-$1.085B and gross margin of 56%-57%. Operating loss narrowed to -$2.4M from -$22.9M a year ago, and adjusted EBITDA improved to $18.0M (6% of sales) from $2.8M (1% of sales).
Key Financial Metrics
Key Facts
- Q3 2026 sales of $283.7M, +14% YoY vs $249.3M, above $265.8M consensus
- GAAP net loss per share -$0.10 vs consensus -$0.24
- Gross margin 57%, up 270 bps YoY from 54%
- Operating loss improved to -$2.4M (-1% of sales) from -$22.9M (-9% of sales)
- Adjusted EBITDA $18.0M (6% of sales) vs $2.8M (1% of sales) a year ago
- Full-year 2026 guidance reaffirmed: sales $1.065B-$1.085B, gross margin 56%-57%
- U.S. pump shipments nearly 23,000, international nearly 11,000
- Pharmacy channel reached 15% of U.S. sales; formulary coverage ~50% of U.S. lives
Financial Impact
Q3 sales beat consensus by $17.9M (6.7%); EPS beat by $0.14 (58.3%); operating loss narrowed by $20.5M YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| United States | $191.0M | +9.0% |
| International | $92.6M | +26.0% |
Risk Factors
- Company still GAAP net loss-making (-$7.1M in Q3, -$48.6M YTD)
- Free cash flow negative at -$5.5M in Q3 and -$39.4M YTD
- Convertible senior notes of $603.4M represent significant leverage
- U.S. pump sales declined 2% YoY in Q3, offset by supplies growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001438133-26-000143 |
| Document: tndm-20261105.htm | 0001438133-26-000143 |
| Document: 0001438133-26-000143-index-headers.html | 0001438133-26-000143 |
| Document: 0001438133-26-000143-index.html | 0001438133-26-000143 |
| Document: 0001438133-26-000143.txt | 0001438133-26-000143 |
| 8-K Data (Synthetic) | 0001438133-26-000143 |
Track record
9 reports on TNDM
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $18.50 Now $18.48 +0.11% settles Nov 18
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $20.00 Now $18.48 −7.60% settles Nov 17
- Nov 13, 20263d ago 8-K Bullish 5/10 Entry $20.07 to $18.48 Now $18.48 −7.92% ▼ −7.92% −6.01% vs SPY
- Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $18.71 to $18.77 Now $18.48 −1.23% ▲ +0.32% −1.00% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $16.91 to $18.17 Now $18.48 +9.28% ▲ +7.45% +5.08% vs SPY
- Oct 27, 202620d ago 144 Neutral 2/10 Entry $19.68 to $19.79 Now $18.48 −6.10% ▲ +0.56% +0.94% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $15.80 to $16.60 Now $18.48 +16.96% ▲ +5.06% +4.52% vs SPY
- May 15, 202626w ago 8-K Neutral 3/10 Entry $12.82 to $13.53 Now $18.48 +44.15% ▲ +5.54% +5.60% vs SPY
- Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $19.35 to $19.68 Now $18.48 −4.50% ▲ +1.71% +1.13% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers